Bicuspid Aortic Valve Clinical Trial
Official title:
Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve
NCT number | NCT06153407 |
Other study ID # | 4-2023-1045 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 19, 2023 |
Est. completion date | October 2028 |
Verified date | November 2023 |
Source | Yonsei University |
Contact | Iksung Cho |
Phone | 82-2-2228-8442 |
iksungcho[@]yuhs.ac | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is to elucidate the impact of germline mutations and clonal hematopoiesis (CHIP) on the progression of early aortic valve calcification in patients with bicuspid aortic valves. The study will be conducted over a recruitment period of one year and a follow-up observation period of two years. Considering a 2-year event rate and a 33% occurrence rate of clonal hematopoiesis, each group requires a minimum of 102 participants. Accounting for a 15% dropout rate, a total of 120 participants are needed for each group (type I error (α) = 5%, type II error (β) = 20%). Therefore, the total study population, including patients with normal aortic valve function, is set at 240 participants.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | October 2028 |
Est. primary completion date | October 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patients with confirmed bicuspid aortic valves based on cardiac imaging (echocardiography, CT, MRI) or surgical findings. 2. Early aortic valve calcification group: Patients aged 20-80 with moderate or greater aortic valve stenosis/regurgitation. 3. Normal functioning aortic valve group: Patients aged 20-80 with mild or less aortic valve stenosis/regurgitation. 4. Patients who understand the purpose of the study and voluntarily consent to participate. Exclusion Criteria: 1. Patients with malignant neoplastic diseases or other conditions, such as cerebrovascular accidents, which predict survival of less than 6 months. 2. Patients with unclear presence of bicuspid aortic valves. 3. Patients with stage 3 or higher chronic kidney disease. 4. Patients with other inherited cardiac conditions. 5. Patients with cognitive impairment or hemodynamically unstable patients who have difficulty understanding the study content. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence of germline mutation | 2 years follow-up | ||
Primary | Clonal hematopoiesis of indeterminate potential (CHIP) mutation | Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of a clonally expanded hematopoietic stem cell caused by a leukemogenic mutation. | 2 years follow-up | |
Secondary | Progression of aortic valve calcification | Progression of aortic valve calcification measured by computed tomography (AV calcium score) or Echocardiography (Progression of AS/AR) | 2 years follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01390181 -
The Effect of Losartan in Bicuspid Aortic Valve Patients
|
N/A | |
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Active, not recruiting |
NCT03635424 -
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
|
N/A | |
Active, not recruiting |
NCT03474159 -
Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve by Multimodal Imaging
|
N/A | |
Not yet recruiting |
NCT06375590 -
NavIIcusp: Bicuspid Aortic Valve Stenosis With Navitor Platform International Experience
|
||
Recruiting |
NCT05739253 -
Changes of Ascending Aortic Diameter in Patients Undergoing Transcatheter Aortic Valve Replacement
|
||
Completed |
NCT01823432 -
Genetic Risks for Bicuspid Aortic Valve Disease
|
||
Completed |
NCT02679261 -
Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve
|
Phase 3 | |
Completed |
NCT01920815 -
Bicuspid Valve Aortopathy Feasibility Study
|
||
Recruiting |
NCT04817735 -
The CASPER Registry
|
N/A | |
Recruiting |
NCT02899624 -
Whole Exome Sequencing in Bicuspid Aortic Valve Patients
|
N/A | |
Recruiting |
NCT05708118 -
Progression of Ascending Aorta Diameters in Bicuspid Aortic Valve After Transcatheter or Surgical Replacement.
|
||
Recruiting |
NCT03495050 -
BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.
|
||
Completed |
NCT01760668 -
Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome
|
N/A | |
Not yet recruiting |
NCT05711693 -
Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV)
|
N/A | |
Completed |
NCT05836363 -
Fate at Long-term of Mild to Moderate Bicuspid Aortic Valve Disease Left Untreated at the Time of Supracoronary Ascending Aorta Replacement
|
||
Completed |
NCT02283970 -
Investigation of Patients With BAV Requiring Valve and/or Aortic Repair (GISSI Outliers VAR)
|
||
Active, not recruiting |
NCT01026571 -
Identification of Genetic Causes of Bicuspid Aortic Valve Disease
|
||
Completed |
NCT00412386 -
Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve
|
N/A | |
Recruiting |
NCT03440697 -
Pathogenetic Basis of Aortopathy and Aortic Valve Disease
|